We are live on
!
Find out more
BGI
B Group Inc Portfolio holdings
AUM
$213M
1-Year Est. Return
96.05%
This Fund
S&P 500
This Quarter
Est. Return
-10.08%
1 Year Est. Return
+96.05%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$164M
AUM Growth
–
Cap. Flow
+$116M
Cap. Flow
% of AUM
70.78%
Top 10 Holdings %
Top 10 Hldgs %
96.62%
Holding
18
New
18
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ADMA Biologics
ADMA
|
+$43M |
| 2 |
Insmed
INSM
|
+$25.2M |
| 3 |
Zai Lab
ZLAB
|
+$11.1M |
| 4 |
Iovance Biotherapeutics
IOVA
|
+$9.2M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$7.87M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 64.54% |
| 2 | Miscellaneous | 35.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
Invesco QQQ Trust
QQQ
$489B
| $56.2M | 34.37% |
+110,000
| New | +$55.6M |
|
|
2
ADMA Biologics
ADMA
$2.15B
| $39.2M | 23.98% |
+2,287,542
| New | +$43M |
|
|
3
Insmed
INSM
$27.6B
| $24.2M | 14.77% |
+350,000
| New | +$25.2M |
|
|
4
Zai Lab
ZLAB
$2.94B
| $10.5M | 6.4% |
+400,000
| New | +$11.1M |
|
|
5
Iovance Biotherapeutics
IOVA
$3.98B
| $7.34M | 4.49% |
+992,000
| New | +$9.2M |
|
|
AKRO
6
DELISTED
Akero Therapeutics
AKRO
| $7.23M | 4.42% |
+260,000
| New | +$7.87M |
|
|
CLLS
7
Cellectis
CLLS
$326M
| $5.55M | 3.39% |
+3,081,501
| New | +$5.75M |
|
8
Aura Biosciences
AURA
$784M
| $3.88M | 2.37% |
+472,576
| New | +$4.45M |
|
9
Sight Sciences
SGHT
$460M
| $2.29M | 1.4% |
+629,370
| New | +$2.87M |
|
10
Taysha Gene Therapies
TSHA
$1.82B
| $1.67M | 1.02% |
+965,556
| New | +$2M |
|
11
CALL
Ultragenyx Pharmaceutical
RARE
$1.51B
| $1.24M | 0.76% |
+29,500
| New | +$1.46M |
|
12
Spyre Therapeutics
SYRE
$7.85B
| $1.16M | 0.71% |
+50,000
| New | +$1.47M |
|
13
Assembly Biosciences
ASMB
$745M
| $799K | 0.49% |
+50,651
| New | +$815K |
|
|
APGE
14
DELISTED
Apogee Therapeutics
APGE
| $680K | 0.42% |
+15,000
| New | +$765K |
|
15
PUT
Corvus Pharmaceuticals
CRVS
$1.21B
| $535K | 0.33% |
+100,000
| New | +$747K |
|
16
BioNTech
BNTX
$26.1B
| $399K | 0.24% |
+3,500
| New | +$399K |
|
|
ORKA
17
Oruka Therapeutics
ORKA
$6.13B
| $388K | 0.24% |
+20,000
| New | +$488K |
|
|
18
Ultragenyx Pharmaceutical
RARE
$1.51B
| $320K | 0.2% |
+7,596
| New | +$377K |
|
Similar funds
WPA
B
CCWP
4FG
KCM
LWP
EWM
HB
B Group Inc's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for B Group Inc, which disclosed 18 positions worth $164M. Its ten largest holdings account for 97% of the portfolio.
Its largest position is ADMA Biologics: 2,287,542 shares worth $39.2M.
By sector, the portfolio is most concentrated in Healthcare at 65% of assets, followed by Miscellaneous.
- B Group Inc's largest Q4 2024 buy was ADMA Biologics: 2,287,542 shares worth $39.2M.
- B Group Inc's ten largest holdings make up 97% of its $164M portfolio in Q4 2024.
- B Group Inc disclosed 18 positions in Q4 2024, its first 13F filing on record.
Based on B Group Inc's 13F filing for Q4 2024, filed 14 Feb 2025.